+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030- Product Image
Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030- Product Image
New

Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 6056002
Description Jump to:
The Pancreatic Cancer Precision Medicine Market was valued at USD 656.8 million in 2024, and is projected to reach USD 1.88 billion by 2030, rising at a CAGR of 19.20%. The pancreatic cancer precision medicine industry experiences growth due to the increasing adoption of targeted therapies and immunotherapies, which enhanced survival rates and minimized side effects. Advanced diagnostic tools, including liquid biopsies and molecular profiling, improved early detection and treatment efficacy. This shift towards precision medicine facilitated more effective, individualized treatment strategies.

Technological progress, specifically the integration of next-generation sequencing and bioinformatics, facilitated the discovery of new therapeutic targets, enabling more effective drug design. Pharmaceutical companies, academic institutions, and government organizations increased their investments, supporting the development of innovative therapies. Initiatives such as the PanCAN grants program demonstrated a commitment to funding pancreatic cancer research, driving market growth.

The rising incidence of pancreatic cancer, influenced by lifestyle factors and an aging population, created a higher demand for specialized treatments. In 2024, Cancer Australia estimated 4,641 new pancreatic cancer cases were diagnosed in the country. This growing prevalence propelled market growth as healthcare providers sought more effective options. Furthermore, strategic collaborations between pharmaceutical companies and research institutions and regulatory support further accelerated market growth.

Pancreatic Cancer Precision Medicine Market Report Highlights

  • Based on therapeutic approach, targeted therapy dominated the market and accounted for a share of 56.0% in 2024, owing to by advancements in personalized treatment and genomic profiling.
  • Chemotherapy-precision combinations, on the other hand, is expected to grow at the fastest CAGR of over the forecast period.
  • Based on diagnostic technology, genomic testing led the market and accounted for 40.8% in 2024. Its role in identifying actionable mutations proved essential for personalized treatment.
  • Liquid biopsies, a minimally invasive method for early detection via ctDNA and CTC analysis, are projected to grow at the fastest CAGR of 20.3% over the forecast period, driven by improved patient outcomes.
  • The increasing adoption of targeted therapies and immunotherapies, coupled with advanced diagnostics, fuels market growth by enhancing survival rates and tailoring effective precision medicine strategies.
  • North America dominated the global pancreatic cancer precision medicine industry with a 42.9% revenue share, driven by high incidence rates and demand for effective treatments.
  • Market players operating in the pancreatic cancer precision medicine industry include AstraZeneca; Pfizer Inc.; Novartis AG; Amgen Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd; PharmaCyte Biotech, Inc.; Genentech, Inc.; Guardant Health; Illumina, Inc.; Thermo Fisher Scientific Inc.; FOUNDATION MEDICINE, INC.
  • In August 2024, Illumina Inc. launched a new oncology menu for its NovaSeq X Series customers, expanding comprehensive genomic profiling at lower costs and greater scale for customers worldwide.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapeutic Approach
1.2.2. Diagnostic Technology
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Pancreatic Cancer Precision Medicine Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Pancreatic Cancer Precision Medicine Market: Therapeutic Approach Business Analysis
4.1. Therapeutic Approach Market Share, 2024 & 2030
4.2. Therapeutic Approach Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Approach, 2018 to 2030 (USD Million)
4.4. Targeted Therapy
4.4.1. Targeted Therapy Market, 2018-2030 (USD Million)
4.5. PARP Inhibitors
4.5.1. PARP Inhibitors Market, 2018-2030 (USD Million)
4.6. Monoclonal Antibodies
4.6.1. Monoclonal Antibodies Market, 2018-2030 (USD Million)
4.7. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors
4.7.1. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors Market, 2018-2030 (USD Million)
4.8. Immunotherapy
4.8.1. Immunotherapy Market, 2018-2030 (USD Million)
4.9. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors
4.9.1. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors Market, 2018-2030 (USD Million)
4.10. Cancer Vaccines - GVAX, Algenpantucel-L
4.10.1. Cancer Vaccines - GVAX, Algenpantucel-L Market, 2018-2030 (USD Million)
4.11. Adoptive T-Cell Therapies - CAR-T Therapies
4.11.1. Adoptive T-Cell Therapies - CAR-T Therapies Market, 2018-2030 (USD Million)
4.12. Chemotherapy-Precision Combinations
4.12.1. Chemotherapy-Precision Combinations Market, 2018-2030 (USD Million)
4.13. Other Therapeutic Approaches
4.13.1. Other Therapeutic Approaches Market, 2018-2030 (USD Million)
Chapter 5. Pancreatic Cancer Precision Medicine Market: Diagnostic Technology Business Analysis
5.1. Diagnostic Technology Market Share, 2024 & 2030
5.2. Diagnostic Technology Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Diagnostic Technology, 2018 to 2030 (USD Million)
5.4. Genomic Testing
5.4.1. Genomic Testing Market, 2018-2030 (USD Million)
5.5. Molecular Diagnostics
5.5.1. Molecular Diagnostics Market, 2018-2030 (USD Million)
5.6. Liquid Biopsy
5.6.1. Liquid Biopsy Market, 2018-2030 (USD Million)
5.7. Biomarker-based Companion Diagnostics
5.7.1. Biomarker-based Companion Diagnostics Market, 2018-2030 (USD Million)
5.8. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)
5.8.1. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry) Market, 2018-2030 (USD Million)
Chapter 6. Pancreatic Cancer Precision Medicine Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.7. Norway
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Norway Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Denmark Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.9. Sweden
6.5.9.1. Key Country Dynamics
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8. MEA
6.8.1. MEA Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. AstraZeneca
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Pfizer Inc.
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Novartis AG
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Amgen Inc.
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. F. Hoffmann-La Roche Ltd
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Bayer AG
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Eli Lilly and Company
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Merck & Co., Inc.
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Teva Pharmaceutical Industries Ltd
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. PharmaCyte Biotech, Inc.
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Genentech, Inc.
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
7.5.12. Guardant Health
7.5.12.1. Overview
7.5.12.2. Financial Performance
7.5.12.3. Product Benchmarking
7.5.12.4. Strategic Initiatives
7.5.13. Illumina, Inc.
7.5.13.1. Overview
7.5.13.2. Financial Performance
7.5.13.3. Product Benchmarking
7.5.13.4. Strategic Initiatives
7.5.14. Thermo Fisher Scientific Inc.
7.5.14.1. Overview
7.5.14.2. Financial Performance
7.5.14.3. Product Benchmarking
7.5.14.4. Strategic Initiatives
7.5.15. FOUNDATION MEDICINE, INC.
7.5.15.1. Overview
7.5.15.2. Financial Performance
7.5.15.3. Product Benchmarking
7.5.15.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global pancreatic cancer precision medicine market, by region, 2018-2030 (USD Million)
Table 4 Global pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 5 Global pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 6 North America pancreatic cancer precision medicine market, by country, 2018-2030 (USD Million)
Table 7 North America pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 8 North America pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 9 U.S. pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 10 U.S. Pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 11 Canada pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 12 Canada pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 13 Mexico pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 14 Mexico pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 15 Europe pancreatic cancer precision medicine market, by country, 2018-2030 (USD Million)
Table 16 Europe pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 17 Europe pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 18 UK pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 19 UK Pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 20 Germany pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 21 Germany pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 22 France pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 23 France Pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 24 Italy pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 25 Italy pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 26 Spain pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 27 Spain pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 28 Norway pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 29 Norway Pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 30 Denmark pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 31 Denmark pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 32 Sweden pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 33 Sweden pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 34 Asia Pacific pancreatic cancer precision medicine market, by country, 2018-2030 (USD Million)
Table 35 Asia Pacific pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 36 Asia Pacific pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 37 Japan pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 38 Japan pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 39 China pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 40 China pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 41 India pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 42 India pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 43 Australia pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 44 Australia pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 45 South Korea pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 46 South Korea pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 47 Thailand pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 48 Thailand pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 49 Latin America pancreatic cancer precision medicine market, by country, 2018-2030 (USD Million)
Table 50 Latin America pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 51 Latin America pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 52 Brazil pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 53 Brazil pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 54 Argentina pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 55 Argentina pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 56 Middle East & Africa Pancreatic cancer precision medicine market, by country, 2018-2030 (USD Million)
Table 57 Middle East & Africa pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 58 Middle East & Africa pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 59 South Africa pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 60 South Africa pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 61 Saudi Arabia pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 62 Saudi Arabia pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 63 UAE pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 64 UAE pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
Table 65 Kuwait pancreatic cancer precision medicine market, by therapeutic approach, 2018-2030 (USD Million)
Table 66 Kuwait pancreatic cancer precision medicine market, by diagnostic technology, 2018-2030 (USD Million)
List of Figures
Figure 1 Pancreatic cancer precision medicine market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and diagnostic technology outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Pancreatic cancer precision medicine market dynamics
Figure 12 Pancreatic cancer precision medicine market: Porter’s five forces analysis
Figure 13 Pancreatic cancer precision medicine market: PESTLE analysis
Figure 14 Pancreatic cancer precision medicine market: Therapeutic approach segment dashboard
Figure 15 Pancreatic cancer precision medicine market: Therapeutic approach market share analysis, 2024 & 2030
Figure 16 Targeted therapy market, 2018-2030 (USD Million)
Figure 17 PARP inhibitors market, 2018-2030 (USD Million)
Figure 18 Monoclonal antibodies market, 2018-2030 (USD Million)
Figure 19 Small molecule inhibitors - EGFR inhibitors, KRAS inhibitors market, 2018-2030 (USD Million)
Figure 20 Immunotherapy market, 2018-2030 (USD Million)
Figure 21 Immune checkpoint inhibitors - PD-1 inhibitors, PD-L1 inhibitors market, 2018-2030 (USD Million)
Figure 22 Cancer vaccines - GVAX, Algenpantucel-L market, 2018-2030 (USD Million)
Figure 23 Adoptive T-Cell therapies - CAR-T therapies market, 2018-2030 (USD Million)
Figure 24 Chemotherapy-precision combinations market, 2018-2030 (USD Million)
Figure 25 Other therapeutic approaches market, 2018-2030 (USD Million)
Figure 26 Pancreatic cancer precision medicine market: Diagnostic technology segment dashboard
Figure 27 Pancreatic cancer precision medicine market: Diagnostic technology market share analysis, 2024 & 2030
Figure 28 Genomic testing market, 2018-2030 (USD Million)
Figure 29 Molecular diagnostics market, 2018-2030 (USD Million)
Figure 30 Liquid biopsy market, 2018-2030 (USD Million)
Figure 31 Biomarker-based companion diagnostics market, 2018-2030 (USD Million)
Figure 32 Others (Immunohistochemistry (IHC), proteomics, mass spectrometry) market, 2018-2030 (USD Million)
Figure 33 Pancreatic cancer precision medicine market revenue, by region
Figure 34 Regional marketplace: Key takeaways
Figure 35 Regional marketplace: Key takeaways
Figure 36 North America pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 37 U.S. country dynamics
Figure 38 U.S. pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 39 Canada country dynamics
Figure 40 Canada pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 41 Mexico country dynamics
Figure 42 Mexico pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 43 Europe pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 44 UK country dynamics
Figure 45 UK pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 46 Germany country dynamics
Figure 47 Germany pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 48 France country dynamics
Figure 49 France pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 50 Italy country dynamics
Figure 51 Italy pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 52 Spain country dynamics
Figure 53 Spain pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 54 Norway country dynamics
Figure 55 Norway pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 56 Sweden country dynamics
Figure 57 Sweden pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 58 Denmark country dynamics
Figure 59 Denmark pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 60 Asia Pacific pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 61 Japan country dynamics
Figure 62 Japan pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 63 China country dynamics
Figure 64 China pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 65 India country dynamics
Figure 66 India pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 67 Australia country dynamics
Figure 68 Australia pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 69 South Korea country dynamics
Figure 70 South Korea pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 71 Thailand country dynamics
Figure 72 Thailand pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 73 Latin America pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 74 Brazil country dynamics
Figure 75 Brazil pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 76 Argentina country dynamics
Figure 77 Argentina pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 78 MEA pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 79 South Africa country dynamics
Figure 80 South Africa pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 81 Saudi Arabia country dynamics
Figure 82 Saudi Arabia pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 83 UAE country dynamics
Figure 84 UAE pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 85 Kuwait country dynamics
Figure 86 Kuwait pancreatic cancer precision medicine market, 2018-2030 (USD Million)
Figure 87 Company categorization
Figure 88 Company market position analysis
Figure 89 Strategic framework

Companies Mentioned

The major companies profiled in this Pancreatic Cancer Precision Medicine market report include:
  • AstraZeneca
  • Pfizer Inc.
  • Novartis AG
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd
  • PharmaCyte Biotech, Inc.
  • Genentech, Inc.
  • Guardant Health
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • FOUNDATION MEDICINE, INC.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 656.8 Million
Forecasted Market Value ( USD ) by 2030 $ 1880 Million
Compound Annual Growth Rate19.2%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

U.S. Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Exocrine, Endocrine), By Treatment (Chemotherapy, Radiation Therapy, Others), By Distribution Channel, And Segment Forecasts, 2025 - 2030 - Product Image

U.S. Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Exocrine, Endocrine), By Treatment (Chemotherapy, Radiation Therapy, Others), By Distribution Channel, And Segment Forecasts, 2025 - 2030

  • Report
  • 130 Pages
  • United States
From
Pancreatic Cancer Therapeutics Market by Type, Product, End-Use - Global Forecast 2025-2030 - Product Image

Pancreatic Cancer Therapeutics Market by Type, Product, End-Use - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Pancreatic Cancer Treatment Market by Affected region, Type - Global Forecast 2025-2030 - Product Image

Pancreatic Cancer Treatment Market by Affected region, Type - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Advanced Pancreatic Cancer Market - Product Image

Advanced Pancreatic Cancer Market

  • Report
  • 250 Pages
  • Global
From
Sunitinib Malate - Global Strategic Business Report - Product Image

Sunitinib Malate - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.